Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases

Trial Title: Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases

NCT ID: NCT05894837

Condition: Colorectal Cancer
Liver Metastases

Conditions: Official terms:
Colorectal Neoplasms
Neoplasm Metastasis
Liver Neoplasms

Conditions: Keywords:
Colorectal Cancer
Regorafenib
hepatic artery bicarbonate infusion
Serplulimab

Study type: Interventional

Study phase: Phase 2

Overall status: Not yet recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Serplulimab+Regorafenib
Description: Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day
Arm group label: Serplulimab in combination with Regorafenib and hepatic artery bicarbonate infusion

Intervention type: Drug
Intervention name: Hepatic Artery Bicarbonate Infusion
Description: hepatic artery bicarbonate infusion: once every four weeks
Arm group label: Serplulimab in combination with Regorafenib and hepatic artery bicarbonate infusion

Summary: A single-center, single-arm, phase 2 trial of Serplulimab in combination with Regorafenib and hepatic artery bicarbonate infusion for third-line treatment in patients with colorectal cancer and liver metastases. A total of 30 patients are planned to be enrolled.

Detailed description: This is a single-center, single-arm, phase 2 trial. Enroll 30 patients with colorectal cancer and liver metastases and failure of standard therapy. Administer serplulimab intravenously(once every two weeks)in combination with regorafenib(from the first day to the 21th day) and hepatic artery bicarbonate infusion (once every four weeks). Medication must be discontinued until disease progression, intolerable toxicity, informed consent is withdrawn, or investigator judgment is made. The primary endpoint is objective response rate (ORR), and secondary endpoints are progression-free survival (PFS), overall survival (OS), and adverse effects (AE).

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Age 18 or above, male or female; 2. Patients with colorectal cancer and liver metastases who strictly conform to the clinical diagnostic criteria of "Chinese Guidelines for Diagnosis and Treatment of Colorectal Cancer (2020 Edition)" or who have been confirmed by histopathology or cytology; 3. At least 1 measurable intrahepatic lesion; 4. Child-Pugh liver function rating: A or good B (≤7 points) ; 5. No local treatment including radiotherapy, surgical excision and ablation was performed before interventional therapy; 6. No other malignant tumors; 7. ECOG score within one week before enrollment: 0-1; 8. Predicted survival ≥24 weeks; 9. The major organs are functioning normally; the following criteria are met: Blood examination: a) HB≥90 g/L；b) ANC≥1.5×109/L；c) PLT≥80×109/L; Biochemical examination: a) ALB ≥29 g/L；b) ALT and AST<5ULN；c) TBIL ≤1.5ULN；d) Creatinine≤1.5ULN；(Only one of the two measures of albumin and bilirubin in the Child-Pugh rating can be a score of 2); Thyroid function tests are within normal range； 10. Women of childbearing age must already be using reliable contraception or have had a pregnancy test (serum or urine) with negative results within 7 days prior to inclusion and be willing to use an appropriate method of contraception during the trial period and 8 weeks after the last test drug administration； 11. The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up； Exclusion Criteria: 1. There is a contraindication of anti-PD-1 monoclonal antibody therapy; 2. With other uncured malignancies, except for cured basal cell carcinoma of the skin and cervical carcinoma in situ; 3. Patients who are preparing for an organ transplant or have had an organ transplant in the past； 4. Ascites with clinical symptoms that require therapeutic abdominal puncture or drainage, or Child-Pugh score > 2； 5. Patients with high blood pressure (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg) who cannot be reduced to the normal range by antihypertensive medication； 6. Patients with grade Ⅱ or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms for males and 470 ms for females); A history of symptomatic ischemic or hemorrhagic cerebrovascular disease； 7. Having multiple factors that affect oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction, which significantly affects drug administration and absorption)； 8. Patients with a history of gastrointestinal bleeding or a definite tendency to gastrointestinal bleeding within the past 6 months, such as esophageal varicose veins with bleeding risk, locally active ulcer lesions, stool occult blood ≥ (++), should not be included in the group; If fecal occult blood (+), gastroscopy is required； 9. Had an abdominal fistula, gastrointestinal perforation, or abdominal abscess in the 28 days prior to joining the study； 10. Patients with abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN+4 seconds) who are prone to bleeding or are receiving thrombolytic or anticoagulant therapy； 11. Patients with central nervous system metastases or known brain metastases； 12. Patients with past and current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, and severe impairment of lung function； 13. Urine routine showed urine protein ≥++ or confirmed 24 hours urine protein quantity > 1.0 g； 14. Severe thyroid disease cannot be controlled by treatment； 15. Rheumatic or autoimmune diseases, and immunosuppressant or high-dose hormone therapy after organ transplantation；

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: the Second Affiliated Hospital of Medical College of Zhejiang University

Address:
City: Hangzhou
Zip: 310000
Country: China

Start date: June 1, 2023

Completion date: June 1, 2025

Lead sponsor:
Agency: Second Affiliated Hospital, School of Medicine, Zhejiang University
Agency class: Other

Source: Second Affiliated Hospital, School of Medicine, Zhejiang University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05894837